LifeSci Capital Initiates Coverage On Eloxx Pharma with Outperform Rating, Announces Price Target of $40

LifeSci Capital analyst Rami Katkhuda initiates coverage on Eloxx Pharma (NASDAQ:ELOX) with a Outperform rating and announces Price Target of $40.